Elanco Animal Health announced the U.S. FDA has approved Zenrelia, a safe, highly effective, and convenient once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming days.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Five Below downgraded, DoorDash upgraded: Wall Street’s top analyst calls
- Elanco downgraded to Equal Weight from Overweight at Morgan Stanley
- Elanco provides update on relationship with TriRx
- Elanco announces Credelio Quattro has moved to final FDA administrative review
- Morning Movers: Eli Lilly and Under Armor jump following earnings beats